Status:
TERMINATED
Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan
Lead Sponsor:
Meiji University of Oriental Medicine
Collaborating Sponsors:
Kyoto Prefectural University of Medicine
Conditions:
Allergic Conjunctivitis
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
Intravenous- injection of beta-1,3-glucan in human is known to induce T helper type 1 response, while oral uptake did not. It was examined whether superfine dispersed beta-1,3-glucan (SDG) contrived t...
Detailed Description
Beta-1,3-glucan made from Japanese mushroom is commercially available for healthy foodstuffs. Allergy patients were orally administrated either SDG (n=30) or non-dispersed beta-1,3-glucan (NDG, n=30) ...
Eligibility Criteria
Inclusion
- history of seasonal allergic conjunctivitis with or without rhinitis in spring (Japanese cedar pollen season) every year
- positive allergen specific IgE (\> 30 IU/ml) or positive skin prick test result (wheal diameter \> 3mm) to Japanese cedar, Orchard Grass pollen, or house dust-mite extract
Exclusion
- Patients who had undergone immunotherapy in the previous 5 years
- a history of other immunological or medically relevant diseases
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
June 1 2004
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00276445
Start Date
January 1 2004
End Date
June 1 2004
Last Update
November 7 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meiji University of Oriental Medicine
Kyoto, Kyoto, Japan, 629-0392